PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This study is a prospective, two-arm, randomized phase II study of talazoparib versus
talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer
harboring HRD scar
1st line treatment: GnRH agonist + Aromatase Inhibitor(AI) + Palbociclib 28 days after the
last treatment of 1st line treatment, randomization for 2nd line treatment is conducte to arm
A(Talazoparib+Atezolizumab) and arm B(Talazoparib monotherapy)